6 lectures · 142 items
11 min
9 min
6 min
5 min
15 min
6 min
Global guideline on the use of GLP-1 medicines in treating obesity issued by WHO
EU Launches Ambitious "Safe Hearts Plan": A New Roadmap in Cardiovascular Health
Introducing GPcardio: Bridging the Gap in Cardiovascular Care
Primary Prevention of Atherosclerotic Cardiovascular Disease (ASCVD) in Primary care: A Systematic Review of Guidelines
Enhanced remote medication program boosts GDMT prescriptions for high CV or kidney risk in T2D patients
Slides | Take home messages of EPCCS Guidance on 'Current management of diabetes and CV risk in primary care'
Slides: Managing diabetes in daily cardiovascular practice: A multidisciplinary approach
Slides: Targeting CVD in diabetes: novel strategies to tackle the risk
Slides: Type 2 Diabetes & CV outcomes: More than Glucose management? - lessons from GLP1-ra trialsEducation, exchange, guidance and interaction during EPCCS Summit 2019
Slides | Diabetes and cardiovascular risk
Slides | What's the evidence that diabetes is linked to CVD risk?Diabetes and cardiovascular risk
Current management of diabetes and cardiovascular risk in primary care 
Slides | Type 2 diabetes & cardiovascular disease updatebalancing euglycaemic ketoacidosis risk and cardiorenal benefits.
This review addresses the perioperative management of SGLT2 inhibitors in patients with heart failure, chronic kidney disease, or type 2 diabetes. While guidelines typically recommend withholding the…
A real-world cohort study of nearly 46,000 patients evaluated whether glucosuria on routine urinalysis serves as a practical proxy for adherence to SGLT2 inhibitors. After inverse probability…
a systematic review.
A systematic review of pooled analyses from the FIDELITY programme demonstrates that finerenone significantly reduces composite renal and cardiovascular outcomes in patients with diabetic kidney…
the CREDENCE trial.
A post-hoc analysis of the CREDENCE trial found that canagliflozin maintains consistent efficacy and safety across varying levels of polypharmacy in patients with type 2 diabetes and chronic kidney…
A Systematic Review and Meta-Analysis.
A systematic review and meta-analysis of 29 randomised controlled trials (n=67,873) evaluated the association between DPP-4 inhibitors and heart failure in adults with type 2 diabetes. Overall, DPP-4…
a multicentre cross-sectional study.
A multicentre cross-sectional study of 15,879 adults in the UK compared five creatinine-based eGFR equations against measured GFR. The Lund-Malmö Revised (LMR) and EKFC equations demonstrated the…
A retrospective cohort study of 382 patients with non-diabetic IgA nephropathy demonstrates that finerenone significantly improves complete renal remission rates (HR 2.58; p < 0.001) and reduces the…
A causal mediation analysis of the pooled FIDELITY trial data (n = 12,143) demonstrates that the cardiovascular benefit of finerenone in patients with type 2 diabetes and chronic kidney disease is…
Intensive blood-pressure lowering reduces mortality and cardiovascular disease in clinical trials, but real-world BP measurements often differ from standardised protocols. In this retrospective…
results from a national registry
Native aortic valve endocarditis is often complicated by heart failure, peri-annular extension and conduction disturbances, making surgery challenging. In this retrospective analysis of the UK NICOR…
target all atherogenic lipoproteins.
Atherosclerotic cardiovascular disease (ASCVD) remains a leading cause of morbidity and mortality in diabetes, partly driven by dyslipidaemia. Although LDL cholesterol (LDL-C) is the primary…
findings from the National Heart Failure Registry, India.
Patients with both heart failure (HF) and diabetes are often prescribed complex regimens, but their impact may depend on social determinants such as educational attainment. This analysis of India's…